BioSpace News Archive

Aspen Neuroscience, Inc. announced that this month it will launch the first patient screening study of its kind.

aTyr Pharma, Inc. today announced a poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting , which is being held April 8 – 13, 2022, in New Orleans, LA, and virtually.

Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced a strategic manufacturing services agreement with National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus’ pipeline.

Zosano Pharma Corporation today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock.

PharmAbcine Inc. announced today that the Company presented an updated preclinical data PMC-309, the Company’s anti-VISTA antibody candidate at AACR (American Association for Cancer Research) 2022.

Israeli startup Sanolla, which provides AI-powered primary care diagnostic solutions, announced that the FDA has granted 510(k) clearance for the clinical use of the AI-ready VoqXTM, the first stethoscope in the world that can listen to infrasound - acoustic waves that cannot be heard by humans.

NEUVOGEN, an immunoncology company, announced that Peter Watler, PhD has been appointed Head, Manufacturing Operations.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s TakeAim Lymphoma study (NCT03328078).

LEO Pharma A/S, a global leader in medical dermatology, today announced 3-year data that help provide insight into the long-term efficacy profile of Adbry™ (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD).

Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference on April 20th , 2022 at 4:30pm ET.